

Resource Summary Report

Generated by [NIF](#) on Jul 31, 2026

PE/Cyanine7 anti-mouse CD8a

RRID:AB_312760

Type: Antibody

Proper Citation

BioLegend Cat# 100721, RRID:AB_312760

Antibody Information

URL: http://antibodyregistry.org/AB_312760

Proper Citation: BioLegend Cat# 100721, RRID:AB_312760

Target Antigen: CD8alpha

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE/Cyanine7 anti-mouse CD8a

Description: This monoclonal targets CD8alpha

Target Organism: mouse

Clone ID: Clone 53-6.7

Antibody ID: AB_312760

Vendor: BioLegend

Catalog Number: 100721

Alternative Catalog Numbers: 100722

Record Creation Time: 20250819T234100+0000

Record Last Update: 20250820T060548+0000

Ratings and Alerts

No rating or validation information has been found for PE/Cyanine7 anti-mouse CD8a.

No alerts have been found for PE/Cyanine7 anti-mouse CD8a.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 54 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Sheban F, et al. (2025) ZEB2 is a master switch controlling the tumor-associated macrophage program. *Cancer cell*, 43(7), 1227.

Li D, et al. (2025) SOSTDC1 downregulation in CD4+ T cells confers protection against obesity-induced insulin resistance. *Cell reports*, 44(4), 115496.

Lecointre M, et al. (2025) HPV16-Expressing Tumors Release Multiple IL1 Ligands to Orchestrate Systemic Immunosuppression Whose Disruption Enables Efficacy of a Therapeutic Vaccine. *Cancer discovery*, 15(7), 1458.

Vrieling F, et al. (2025) Protocol for measuring cellular energetics through noncanonical amino acid tagging in human peripheral blood and murine tissue immune cells. *STAR protocols*, 6(4), 104134.

Qian J, et al. (2025) A CXCR4 partial agonist improves immunotherapy by targeting immunosuppressive neutrophils and cancer-driven granulopoiesis. *Cancer cell*, 43(8), 1512.

Coulibaly ASK, et al. (2025) Id2 levels determine the development of effector vs. exhausted tissue-resident memory CD8+ T cells during CNS chronic infection. *Cell reports*, 44(6), 115861.

Murphy MK, et al. (2025) The transcriptional repressor BLIMP1 enforces TCF-1-dependent and -independent restriction of the memory fate of CD8+ T cells. *Immunity*, 58(10), 2472.

Frisch AT, et al. (2025) Redirecting glucose flux during in vitro expansion generates epigenetically and metabolically superior T cells for cancer immunotherapy. *Cell metabolism*, 37(4), 870.

Misel-Wuchter KM, et al. (2025) Developmental epigenetic programming by Tet1/3 determines peripheral CD8 T cell fate. *EMBO reports*, 26(10), 2494.

Gao C, et al. (2025) Cancer vaccine from intracellularly gelated tumor cells functionalized with CD47 blockage and damage-associated molecular pattern exposure. *Cell reports. Medicine*, 6(5), 102092.

Galan-Cobo A, et al. (2025) KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer. *Cancer cell*, 43(8), 1530.

Kandasamy M, et al. (2025) Glycogen synthase kinase-3 is essential for Treg development and function. *Cell reports*, 44(9), 116256.

Hyslop S, et al. (2025) CD7 regulates the persistence of terminally exhausted CD8+ T cells during chronic infection. *Cell reports*, 44(10), 116316.

Gastaldi T, et al. (2025) Multi-omics and functional characterization of the tumor-killing capacity of Imiquimod-activated plasmacytoid dendritic cells. *iScience*, 28(6), 112670.

Fang X, et al. (2025) The m6A reader HNRNPC is a key regulator in DSS-induced colitis by modulating macrophage phenotype. *iScience*, 28(3), 111812.

Zeng Q, et al. (2025) ORMDL3 restrains type I interferon signaling and anti-tumor immunity by promoting RIG-I degradation. *eLife*, 13.

Lang PA, et al. (2025) Optimized arenaviruses with tumor-tropic mutations promote safe anti-tumor efficacy via sustainable immune modulatory properties. *Cell reports. Medicine*, 6(10), 102411.

Lad M, et al. (2024) Glioblastoma induces the recruitment and differentiation of dendritic-like "hybrid" neutrophils from skull bone marrow. *Cancer cell*, 42(9), 1549.

Ping Y, et al. (2024) PD-1 signaling limits expression of phospholipid phosphatase 1 and promotes intratumoral CD8+ T cell ferroptosis. *Immunity*, 57(9), 2122.

Wang HC, et al. (2024) Kmt2c restricts G-CSF-driven HSC mobilization and granulocyte production in a methyltransferase-independent manner. *Cell reports*, 43(8), 114542.